Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Gallopamil binding to human serum proteins

  • 14 Accesses

  • 9 Citations


We have determined the extent and variability in the binding of gallopamil to human serum proteins. Binding was determined by equilibrium dialysis in healthy volunteer serum, human serum albumin (45 g·l−1), and alpha-1 acid glycoprotein (AAG) (600 mg·l−1) at a pH of 7.4.

Nonlinear regression analysis of gallopamil binding over a wide range of concentrations (10−9 to 10−4 M) in healthy volunteer serum suggested two classes of binding sites (kass.1=4.7×105M−1, kass.2=4.1×104M−1). These values were in close agreement with those obtained from binding to AAG and human serum albumin.

Gallopamil free fraction over the concentration range of 10 to 100 ng·ml−1 was independent of concentration. The free fraction in 20 volunteers was 0.075 at a concentration of 10 ng·ml−1. Gallopamil free fractions were also determined in human serum albumin, to which various concentrations of AAG were added. Bound/free ratios correlated with AAG.

As we changed the pH of the serum from 7.0 to 8.0, the free fraction changed from 0.1 to 0.05.

Verapamil, lignocaine, procainamide, propranolol, 40H-propranolol, MEGX, and NAPA all caused an increase in the free fraction of gallopamil in serum. However, tocanide, quinidine, diltiazem, GX, norverapamil, D620, D617, and desacetyl diltiazem had no effect on gallopamil binding.

Therefore, the data strongly suggest AAG as the high affinity, low capacity binding site and albumin as the low affinity, high capacity binding site for gallopamil, variability in gallopamil binding can be explained by alterations in AAG concentrations, pH, and the presence of other drugs and their metabolites.

This is a preview of subscription content, log in to check access.


  1. 1.

    Fleckenstein A (1971) Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie L (eds) Calcium and the Heart. Academic Press, London New York, pp 131–181

  2. 2.

    Stieren B, Buhler V, Hege HG, Hollman M, Neuss H, Schlepper M, Weymann J (1983) Pharmacokinetics and metabolism of gallopamil. In: Kaltenbach M, Hopf R (Hrsg) Gallopamil, Pharmakologisches und klinisches Wirkungsprofil eines Kalziumantagonisten. Springer, Berlin Heidelberg New York

  3. 3.

    Piafsky KM (1980) Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 5: 246–262

  4. 4.

    Zini R, Barre J, Defer G, Jeanniot JP, Houin G, Tillement JP (1985) Protein binding of propisomide. J Pharm Sci 74: 530–533

  5. 5.

    Denson D, Coyle D, Thompson G, Myers J (1984) Alpha-1-acid glycoprotein and albumin in human serum bupivacaine binding. Clin Pharmacol Ther 35: 409–415

  6. 6.

    Jusko WJ, Gretch M (1976) Plasma and tissue protein binding of drugs. Pharmacokinet Drug Metab Rev 5: 43–140

  7. 7.

    Yost RL, DeVane L (1985) Diurnal variation of alpha-1 acid glycoprotein concentration in normal volunteers. J Pharm Sci 74: 777–779

  8. 8.

    Caplin JL, Johnston A, Hamer J, Camm AJ (1985) The acute changes in serum binding of disopyramide and flecainide after myocardial infarction. Eur J Clin Pharmacol 28: 253–255

  9. 9.

    Giardina EV, Raby K, Freilich D, Vita J, Brem R, Lovie M (1985) The course of alpha-1 acid glycoprotein and its relation to myocardial enzymes after acute myocardial infarction. Am J Cardiol 56: 262–265

  10. 10.

    Routledge PA, Barchowsky BS, Bjornsson TD, Kitchell BB, Shand DG (1980) Lidocaine plasma protein binding. Clin Pharmacol Ther 27: 347–351

  11. 11.

    Martyn JAJ, Abernethy DR, Greenblatt DJ (1984) Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther 35: 535–539

  12. 12.

    Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG (1985) Determinants of plasma alpha-1 acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol 20: 500–502

  13. 13.

    Piafsky KM, Borga O (1977) Plasma protein binding of basic drugs. II. Importance of alpha-1 acid glycoprotein for inter-individual variation. Clin Pharmacol Ther 22: 545–549

  14. 14.

    McNamara PJ, Slaughter RL, Pieper JA, Wyman MG, Lalka D (1981) Factors influencing serum protein binding of lidocaine in humans. Anesth Analg 60: 395–400

  15. 15.

    Bendayan R, Pieper JA, Stewart RB, Caranasos GJ (1984) Influence of age on serum protein binding of propranolol. Eur J Clin Pharmacol 26: 251–254

  16. 16.

    Wilkinson GR, Shand DG (1975) A physiological approach to hepatic durg clearance. Clin Pharmacol Ther 18: 377–390

  17. 17.

    Huang J (1983) Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci 72: 1368–1369

  18. 18.

    Geigy Pharmaceuticals (1962) Scientific Tables. In: Diem K, Lentner C (eds) Documenta Geigy, New York

  19. 19.

    Rosenthal HE (1967) A graphical method for the determination and presentation of binding parameters in a complex system. Anal Biochem 20: 525–532

  20. 20.

    Metzler GM, Elfring GL, McEwen AJ (1974) A user's manual for NONLIN and associated programs. Kalamazoo, MI, The Upjohn Company

  21. 21.

    Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672

  22. 22.

    Sager G, Nilsen OG, Jacobsen S (1979) Variable binding of propranolol in human serum. Biochem Pharmacol 28: 904–911

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rutledge, D.R., Pieper, J.A. Gallopamil binding to human serum proteins. Eur J Clin Pharmacol 33, 375–380 (1987). https://doi.org/10.1007/BF00637633

Download citation

Key words

  • gallopamil
  • plasma protein binding
  • alpha-1 acid glycoprotein